Pillar 1 - FTO (new thread), page-1467

83 citations of Su et al and we're still not getting a name drop:

https://www.mdpi.com/2073-4425/12/9/1375/htm#

"A growing body of evidence has shown that epigenetic regulators are essential for the reversal of the process of misregulation [29]. An RNA methylation-targeted system using a Cas13-directed methyltransferase has potential and has been used with encouraging results [30]. In recent years, a set of specific or non-specific small molecule m6A inhibitors have shown strong anti-tumor effects in many types of cancer [31,32]. Yankova et al. [32] revealed that STM2457 is a highly effective and selective METTLE3 inhibitor, which can reduce the growth of acute myeloid leukemia (AML) and increase differentiation and apoptosis. AML mice treated with STM2457 prolonged their survival. Similarly, two small-molecule FTO inhibitors (CS1 and CS2) have been shown to significantly attenuate the self-renewal and reprogram immune response of leukemia stem/starter cells by suppressing the expression of immune checkpoint genes [31]. These studies highlight the broad potential of targeting m6A for cancer therapy."